Role of CD73 in Disease: Promising Prognostic Indicator and Therapeutic Target

被引：23

作者：

Yang, Jiayin ^{[1
,2
]}

Liao, Xiaohong ^{[3
]}

Yu, Jerry ^{[4
]}

Zhou, Ping ^{[1
]}

机构：

[1] Fudan Univ, Sch Basic Med Sci, Dept Physiol & Pathophysiol, 138 Yixueyuan Rd, Shanghai 200032, Peoples R China

[2] Dent Dis Prevent & Treatment Ctr Jiading Dist, Shanghai 201899, Peoples R China

[3] Ganzhou Peoples Hosp, Dept Oncol, Ganzhou 341000, Peoples R China

[4] Univ Louisville, Dept Med, Louisville, KY 40292 USA

来源：

CURRENT MEDICINAL CHEMISTRY | 2018年 / 25卷 / 19期

关键词：

CD73; ecto-5 '-nucleotidase; cancer; immunity; inflammation; disease; ENDOTHELIAL BARRIER FUNCTION; VASCULAR ADHESION PROTEIN-2; MALIGNANT EPITHELIAL-CELLS; ECTO-5'-NUCLEOTIDASE CD73; EXTRACELLULAR ADENOSINE; HIGH EXPRESSION; PROTECTIVE ROLE; IFN-BETA; T-CELLS; 5'-ADENOSINE MONOPHOSPHATE;

D O I：

10.2174/0929867325666180117101114

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

CD73, also known as ecto-5'-nucleotidase (eN, NT5E, EC3.13.5), is the rate limiting enzyme for adenosine generation and is expressed on multiple cells. Its expression is significantly influenced by hypoxia and inflammatory factors. During inflammation, CD73 protects endothelial barrier function and inhibits leukocyte trafficking. CD73 also promotes M2 macrophages (anti-inflammatory phenotype). In addition, CD73 is expressed on Treg cells and mediates immune suppression through adenosine. CD73 serves as an essential regulator for the immunity and inflammation. Its expression is related to many diseases, such as autoimmune diseases, ischemia-reperfusion injuries, arterial calcifications, and atherosclerosis. CD73 is overexpressed in many cancers. Its expression is positively associated with tumor growth, metastasis, angiogenesis, poor prognosis and resistance to chemotherapy. Thus, CD73 may be used for prognostic indicator and therapeutic target in diseases such as cancers.

引用

页码：2260 / 2271

页数：12

共 50 条

[21] CD73 as a Novel Prognostic Marker of Pancreatic Adenocarcinoma
Katsuta, E.
Hochwald, S.
Takabe, K.
ANNALS OF SURGICAL ONCOLOGY, 2017, 24 : S114 - S115
[22] The role of CD73 in the adenosinergic response to hypoxia
Thompson, Linda
PURINERGIC SIGNALLING, 2010, 6 : 31 - 31
[23] A short review of CD73 Role in Cancer
Akbari, Farhad Hariri
Slemc, Lucija
Alizadeh, Mahdi
Fard, Mahnaz Hatami
Shafaei, Peymaneh
RESEARCH JOURNAL OF BIOTECHNOLOGY, 2021, 16 (07): : 211 - 219
[24] CD73 and Adenosine Receptor Signaling as a Potential Therapeutic Target in EGFR-Mutated NSCLC
Pacheco, Jose M.
Schenk, Erin L.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : 509 - 511
[25] Regulation and trafficking of CD73 in health and disease
Fausther, Michel
Lavoie, Elise G.
Goree, Jessica R.
Baldini, Giulia
Dranoff, Jonathan A.
PURINERGIC SIGNALLING, 2014, 10 (04) : 700 - 700
[26] An overview of current therapeutic strategies for glioblastoma and the role of CD73 as an alternative curative approach
S. Arab
F. Hasannejad
Clinical and Translational Oncology, 2022, 24 : 742 - 756
[27] An overview of current therapeutic strategies for glioblastoma and the role of CD73 as an alternative curative approach
Arab, S.
Hasannejad, F.
CLINICAL & TRANSLATIONAL ONCOLOGY, 2022, 24 (05): : 742 - 756
[28] DEEP SEQUENCING OF HCC ENDOTHELIUM REVEALS AN ACTIVE ROLE IN IMMUNOSUPPRESSION AND HIGHLIGHTS THE ECTO NUCLEOTIDASE CD73 AS A POTENTIAL THERAPEUTIC TARGET
Faulkes, Rosemary
O'Rourke, Joanne
Cain, Owen
Patten, Daniel
Wilkinson, Alex
Shah, Tahir
Weston, Christopher
GUT, 2021, 70 : A1 - A1
[29] CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer
Leclerc, Bruno G.
Charlebois, Roxanne
Chouinard, Guillaume
Allard, Bertrand
Pommey, Sandra
Saad, Fred
Stagg, John
CLINICAL CANCER RESEARCH, 2016, 22 (01) : 158 - 166
[30] Prognostic impact of CD73 expression in epithelial ovarian cancer
Park, Junsik
Kim, Nari
Lee, Yong Jae
Kim, Sunghoon
Kim, Sang Wun
Lee, Jung-Yun
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (SUPPL_4) : A91 - A91

← 1 2 3 4 5 →